Repligen (NASDAQ:RGEN) Cut to Sell at StockNews.com

StockNews.com lowered shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research note published on Thursday.

RGEN has been the topic of several other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Stock Down 1.4 %

RGEN stock opened at $144.46 on Thursday. The stock has a market capitalization of $8.09 billion, a P/E ratio of -390.42, a P/E/G ratio of 4.64 and a beta of 0.96. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The firm has a 50-day simple moving average of $144.18 and a 200-day simple moving average of $141.73. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 earnings per share. Equities analysts forecast that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. Andra AP fonden acquired a new stake in shares of Repligen during the 2nd quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in Repligen during the second quarter worth about $33,000. UMB Bank n.a. increased its position in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the period. Finally, Resources Management Corp CT ADV acquired a new position in shares of Repligen in the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.